Dana Farber Deal: Potential to Slash Healthcare Costs?
TL/DR –
Dana Farber Cancer Institute is leaving its affiliation with Brigham and Women’s Hospital to partner with Beth Israel Deaconess Medical Center, allowing it to build a larger free-standing acute care hospital. This decision could potentially lessen the market influence of Mass General Brigham, if a health insurance concept that excludes Massachusetts General and Brigham and Women’s as in-network providers is adopted. However, there are concerns that the realignment may lead to increased cancer inpatient spending, particularly as Dana Farber, which is currently the most expensive academic hospital in Massachusetts, plans to expand from 30 beds to potentially 300.
Dana Farber Cancer Institute Ends Long-Term Affiliation With Brigham and Women’s Hospital
The Dana Farber Cancer Institute has decided to end its long-standing association with Brigham and Women’s Hospital to join forces with Beth Israel Deaconess Medical Center which has offered to construct a more expansive acute care hospital on its campus.
This move from the largest healthcare system, Mass General Brigham, to the second-largest, Beth Israel Lahey, has stirred curiosity about the future of healthcare in Massachusetts. The Dana Farber and Brigham and Women’s affiliation will not end until 2028, raising questions about the interim care and the future of healthcare costs in the state as Dana Farber plans to expand from 30 to 300 beds.
Impact on Health Care Spending
One crucial aspect to consider is whether this move could potentially slow down the growth in healthcare spending. There’s a possibility that this re-alignment of cancer care could pave the way for health plan offerings that could impact overall healthcare pricing by breaking the Mass General Brigham’s dominance over Massachusetts healthcare market.
With the dissolution of the Dana Farber-Brigham and Women’s partnership, there might be a chance to reduce the market power of Mass General Brigham, which could help control healthcare prices.
Future Prospects of the Affiliation
From 2028, the new affiliation could provide a package with in-network access to all Boston-area health providers, excluding Massachusetts General and Brigham and Women’s, but including specialty hospitals — Boston Children’s and Dana Farber. This could potentially attract people to buy health plans that exclude Massachusetts General and Brigham and Women’s as in-network providers.
Beth Israel Lahey Health and Dana Farber will need to maintain their commercial prices to ensure sufficient premium savings in plans that exclude Mass General Brigham as in-network. Also, for this to be successful, there shouldn’t be a significant rise in cancer inpatient spending at Dana Farber.
The state needs to scrutinize and approve the new re-alignment and it would be beneficial if the Health Policy Commission could provide an overview of cancer care in Massachusetts. This could help in making informed regulatory decisions and potentially require some constraints on Dana Farber’s commercial prices for both inpatient and outpatient care.
For this proposal to be successful in the next five years, it has to benefit both cancer patients and premium payers, and this could potentially occur with the correct intentions from providers and sensible government oversight.
Read More Health & Wellness News ; US News